Saint Petersburg, FL, Nov. 01, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Apotheca Biosciences (OTC PINK: PCFP), a developer of cutting-edge medical products, nutraceuticals, drug formulations and cannabis delivery technologies for the healthcare and consumer care industry, announces today the addition of Dr. Herbert Weissbach to the Scientific Advisory Board of Apotheca Biosciences as Scientific and Strategic Advisor.
Dr. Weissbach is Professor Emeritus at the Center for Molecular Biology and Biotechnology (CMBB) at Florida Atlantic University (FAU). He received his chemistry degree from the College of the City of New York and his PhD in the field of biochemistry from George Washington University. Dr. Weissbach completed his postdoctoral work at the University of California at Berkeley, in the laboratory of Prof. H.A. Barker, where he discovered the coenzyme form of vitamin B12. Dr. Weissbach spent 16 years doing research at the National Institutes of Health before moving to the pharmaceutical company Hoffmann-La Roche, where he was a co-founder and later Director of the Roche Institute of Molecular Biology and a Vice President of Research. In 1997 he joined FAU and established the CMBB.
Dr. Weissbach’s primary research interest at FAU has been the role of oxidative damage in aging and age-related diseases, and more specifically the mechanisms that cells use to protect against oxidative damage. Among his numerous achievements, his laboratory discovered the methionine sulfoxide reductase (Msr) system that can repair oxidative damage to proteins and is involved in life span extension in both flies and worms. The Msr studies led to research on the drug sulindac, which has the unique properties of protecting normal cells against oxidative damage, but making cancer cells more sensitive to oxidative stress. The National Institute of Aging Interventions Testing Program is currently testing sulindac for life extension in mice.
He has more than 460 publications and among his many honors and awards, including being an elected Member of the National Academy of Sciences and the American Academy of Microbiology and the National Academy of Inventors.
“I’m excited to welcome Dr. Herbert Weissbach to the research team of Apotheca Biosciences,” said Sam Talari, Chief Executive Officer at Apotheca Biosciences. “He provides a great blend of basic academic research and pharmaceutical experience that can help us develop agents that will have an impact on patient’s lives.”
Apotheca Biosciences is at the forefront of medical technologies with the development of a CBD pain patch for the healthcare and consumer care industry. We look forward to the knowledge and expertise that Dr. Weissbach will bring to the development of this product, along with our other products. Our pipeline of products includes transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids.
Apotheca Biosciences is a pioneering biotech company with an emphasis in research and development in addition to the creation of high-grade nutraceuticals and cosmetics. The health of our customers takes precedence and our solid business strategy ensures focus on customer well-being. Our goal is to lay the groundwork and continue research of cannabinoid receptiveness in patients and create nutraceuticals that reflects our strategy and research. For more information on Apotheca Biosciences, please visit www.apothecabiosciences.com or www.apothecabio.com.
Apotheca Biosciences is developing revolutionary formulas and medical delivery systems to transform treatment methods from Pain relief to Alzheimer’s. With the growing understanding of the effectiveness of CBD, it is impossible not to be a part of the growing CBD industry and Apotheca Biosciences will be at the forefront.
About Apotheca Biosciences Inc.
Apotheca Biosciences, through its divisions, develops novel cannabinoid delivery devices for dispensing effective dose concentrations to treat different human diseases, OTC drug formulations, and pharmaceutical research. Apotheca’s research and development includes specific delivery devices to treat Alzheimer’s disease, Parkinson’s disease and severe, chronic pain. For each of these diseases, there is a dire need for targeted delivery of cannabinoid-based actives. Its pipeline of products includes transdermal, sublingual, and nasal delivery technologies for precise and controlled dosing of cannabinoids. Apotheca believes that it can deliver meaningful benefits using its technologies to the world’s aging population.
To request further information about Apotheca, please email info@apothecabio.com, or visit its website at http://www.apothecabiosciences.com/, or visit it on FB @apotheca and Twitter @apotheca
Forward-Looking Statements
This press release may contain forward-looking statements covered within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words "plan," "expect," "believe," and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.